Johnson & Johnson

Latest Headlines

Latest Headlines

Geron jumps as its J&J-partnered cancer drug shows promise in Phase II

Long-troubled drug developer Geron is touting what it calls "unprecedented" early results for its lead cancer drug, sending the biotech's share price up as it moves forward with partner Johnson & Johnson.

UPDATED: J&J-Bayer and Pfizer-BMS look for marketing advantages in real-world Xarelto, Eliquis data

Johnson & Johnson and Bayer are leading the four-horse race among new-age anticoagulants, and they're hoping some new real-world safety data for Xarelto can help keep the med in the No. 1 spot.

Recall roundup: CareFusion infusion pump, J&J sedation device, Teleflex endobronchial tube

The FDA recently deemed corrective actions to three devices as Class 1, reserved for situations in which "there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."

J&J brings 500 jobs to Florida with new shared services HQ

New Jersey-based pharma giant Johnson & Johnson already has a presence in Florida, but it's about to get bigger--by 500 jobs.

J&J and PCH launch hardware startup accelerator

Johnson & Johnson is joining forces with hardware manufacturing company PCH to launch a consumer-health focused hardware startup incubator, building on J&J's commitment to investing in early-stage companies to spur med tech innovation.  

J&J positions blockbuster contender daratumumab for a multiple myeloma showdown

Johnson & Johnson and Genmab have played another card in their deck of data on the multiple myeloma blockbuster contender daratumumab, spelling out some encouraging data that's now being used to help persuade the FDA to deliver a fast marketing approval.

J&J uses share-the-wisdom approach to spread the word on Prezcobix

Johnson & Johnson is trying a new tack on the old "Talk to your doctor" advice. With a new campaign for its HIV drug Prezcobix, the company is urging potential patients to snap a photo and send it to their physicians to see if the drug is right for them.

Takeda takes unexpected blow as blockbuster Velcade patent ruled invalid

With approvals in the U.S and Europe expected soon, it looked like Takeda would have time to get its new multiple myeloma treatment into the market before patents fell off of blockbuster Velcade in 2022. But CEO Christophe Weber may need to plot a new strategy after a federal judge overturned a key patent, putting the Japanese drugmaker's drug vulnerable to generics 5 years early.

Australia's TGA registers Hospira's Inflectra

Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.

J&J working with nonprofit to enable open-source software to combine diabetes device data

Johnson & Johnson's Animas is working with Type 1 diabetes technology nonprofit Tidepool to use its open-source software platform to assemble and analyze data for diabetes device, fitness and food tracking. The news comes in the wake of announcements in recent months from major diabetes device makers, including Medtronic, DexCom and Insulet, that they are partnering with startup Glooko to similarly enable connectivity as well as data transmission and analysis.